Court rules for Bayer on Avelox patents
German pharmaceutical company Bayer HealthCare has prevailed in a legal dispute over two of its US patents on the antibiotic Avelox (moxifloxacin), which had been challenged by Dr Reddy's Laboratories, the US unit of the like-named Indian drug major.
The US District Court for the District of Delaware ruled in favor of Bayer, rejecting all Dr Reddy's challenges to the validity and enforceability of both Bayer patents, which cover active ingredient, composition and methods of treatment. The patents in question run until 2014.
The US subsidiary of Israeli drugmaker Teva Pharmaceuticals Industries has also challenged the validity of the same patents, in a law suit which is set to be heard in the Delaware court in February next year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze